SHORT RESEARCH ARTICLE

Mutation detection in cholestatic patients using microarray resequencing of \textit{ATP8B1} and \textit{ABCB11} [version 1; referees: 1 approved, 1 approved with reservations]

Kirsten E McKay\textsuperscript{1,2}, Christopher K Bruce\textsuperscript{1}, Jane L Hartley\textsuperscript{3}, A S Knisely\textsuperscript{4}, Ulrich Baumann\textsuperscript{5}, Sonja-Stephanie Bockisch\textsuperscript{5}, Ekkehard Sturm\textsuperscript{6}, Christian J Hendriksz\textsuperscript{7}, Deidre A Kelly\textsuperscript{3}, Fiona Macdonald\textsuperscript{2}, Paul Gissen\textsuperscript{8}

\textsuperscript{1}University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
\textsuperscript{2}Birmingham Women’s Hospital, Birmingham, B15 3TG, UK
\textsuperscript{3}Birmingham Children’s Hospital, Birmingham, B4 6NH, UK
\textsuperscript{4}Institute of Liver Studies, King’s College Hospital, London, London, SE5 9RS, UK
\textsuperscript{5}Medizinische Hochschule Hannover, Hannover, 130625, Germany
\textsuperscript{6}University of Tübingen, Tübingen, 72074, Germany
\textsuperscript{7}Salford Royal NHS Foundation Trust, Salford, M6 BHD, UK
\textsuperscript{8}Great Ormond Street Hospital for Children, London, WC1N 3JH, UK

Abstract

\textbf{Background:} Neonatal cholestasis is a common presentation of childhood liver diseases and can be a feature of various conditions including disorders of bile acid biogenesis and transport, various inborn errors of metabolism and perinatal infections. Some inherited metabolic diseases can be easily screened using biochemical assays, however many can only be accurately diagnosed by DNA sequencing. Fluorescent capillary Sanger sequencing (FS) is the gold standard method used by clinical laboratories for genetic diagnosis of many inherited conditions; however, it does have limitations. Recently microarray resequencing (MR) has been introduced into research and clinical practice as an alternative method for genetic diagnosis of heterogeneous conditions. In this report we compared the accuracy of mutation detection for MR with FS in a group of patients with ‘low-normal’ gamma glutamyl transpeptidase (gGT) cholestasis without known molecular diagnoses.

\textbf{Methods:} 29 patient DNA samples were tested for mutations in the \textit{ATP8B1} and \textit{ABCB11} genes using both FS and MR. Other known causes of “low gGT cholestasis” such as ARC syndrome and bile acid biosynthesis disorders were excluded.

\textbf{Results:} Mutations were identified in 13/29 samples. In 3/29 samples FS and MR gave discordant results: MR had a false positive rate of 3.4% and a false negative rate of 7%.

\textbf{Conclusions:} The major advantage of MR over FS is that multiple genes can be screened in one experiment, allowing rapid and cost-effective diagnoses. However, we have demonstrated that MR technology is limited in sensitivity. We therefore recommend that MR be used as an initial evaluation, with FS deployed when genetic and clinical or histopathological findings are discordant.
**Introduction**

Neonatal cholestasis is characterised by persistent hyperbilirubinaemia and has an incidence of around 1 in 2500 live births. It can occur as a result of impaired bile acid biosynthesis, defective bile secretion by hepatocytes (due to membrane transporter defects), or extrahepatic obstruction to biliary flow. Patients present with jaundice, dark urine, pale acholic stools and hepatomegaly. Older infants may have pruritus, develop fat-soluble vitamin deficiencies and fail to thrive. The aetiology of cholestasis is varied and includes multiple inherited causes, such as progressive familial intrahepatic cholestasis (PFIC), Niemann-Pick disease type C and arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome. Furthermore cholestasis can be subdivided into ‘low-normal’ and high gamma glutamyl transpeptidase (gGT) categories depending on the level of serum gGT activity.

Accurate diagnosis is essential in order to inform decisions on treatment and management. As an example, familial intrahepatic cholestasis 1 (FIC1) protein deficiency caused by mutations in \( \text{ATP8B1} \) (PFIC type 1) and bile salt export protein (BSEP) deficiency caused by mutations in \( \text{ABCB11} \) (PFIC type 2) have similar presentations, however liver transplantation is used more frequently in PFIC type 2 than type 1. Genetic testing allows accurate assessment of the genetic risk of cholestasis in families, in addition to providing definitive diagnoses. Clinical laboratories tend to use fluorescent capillary sequencing (FS; Sanger method), because it lends itself to automation and is highly sensitive. However, FS is limited by machine capacity and relatively high consumables costs.

Microarray resequencing (MR) is an alternative sequencing method previously used to detect mutations in patients with intrahepatic cholestasis. We have performed initial testing of a 300kb custom-designed microarray (Birmingham ReseqUencing Microarray, BRUM1) in patients with known mutations. BRUM1 includes probes to sequence two genes (\( \text{ATP8B1} \) and \( \text{ABCB11} \)) involved in PFIC. This short research article describes further evaluation of the BRUM1 microarray using samples simultaneously tested by FS and MR in patients without previously known mutations and assesses the advantages and disadvantages of MR in clinical laboratory use.

**Materials and methods**

**DNA samples**

DNA samples from 29 children (15 females) who presented with intrahepatic cholestasis in the first year of life, low-normal range gGT activity without ARC syndrome or defects in bile acid biosynthesis were used. ARC syndrome was excluded by clinical examination and bile acid biosynthesis disorders were excluded by determination of urinary bile acid profile by electrospray ionisation mass spectrometry. Thus there was a high likelihood of detecting mutations in \( \text{ATP8B1} \) and \( \text{ABCB11} \) in these samples. The study was approved by South Birmingham Research Ethics committee (reference number CA/5175).

**Polymerase chain reaction**

Polymerase chain reaction was used to amplify the coding exons of \( \text{ATP8B1} \) and \( \text{ABCB11} \) plus the intron-exon boundaries prior to both FS and MR. The PCR reaction used 50ng of DNA, 0.5μM each primer (Sigma), 0.5mM dNTPs (Bioline) and 2 units of Taq DNA polymerase (Biomix Red, Bioline UK) in 1x PCR buffer.

**Fluorescent sanger sequencing**

5μl of PCR product was treated with ExoSap IT (GE Healthcare) for 30 mins at 37°C before being denatured at 85°C for 15 mins. Sequencing primers (at a final concentration of 0.5μM) was added to 1μl of BigDye 3.1 and 1x BigDye buffer (Applied Biosystems) in a final volume of 10μl. The sequencing programme was thermal cycling for 34 cycles of denaturing at 95°C for 20 seconds, annealing 50°C for 20 seconds and extension at 60°C for 4 minutes. Resulting products were precipitated using EDTA/Na acetate and ethanol and centrifuged at 4000 rpm for 30 minutes. Products were washed in 70% ethanol before being air dried, resuspended in 10μl of HiDi formamide (Applied Biosystems) and denatured. Resuspended products were analysed using a DNA analyzer 3730xl (Applied Biosystems) and the resulting sequence traces were analysed using Sequence Analysis 5.2.2 (Applied Biosystems).

**Microarray resequencing**

PCR product quantitation, pooling, fragmentation, labelling and hybridisation were performed according to the GeneChip Custom Resequencing Array Protocol V2.1 (Affymetrix). Arrays were washed and stained using a FS450 fluids station before being scanned with a GCS3000 7G scanner (Affymetrix). Intensity files were generated using AGCC (Command Console V1.0, Affymetrix) and processed in GSeq 4.1 (Affymetrix). Base calling assumed the diploid model and a quality score threshold of 2 (default settings were used for all other parameters).

**Results**

\( \text{ATP8B1} \) and \( \text{ABCB11} \) were analysed using FS and MR. The sequence variants detected in 13 of the samples (44.5% detection rate) are listed in Table 1. Eight variants had previously been described in association with PFIC and ten variants were novel. Four of the variants were nonsense mutations (22%), two were splice site changes (11%) and the rest were missense (67%). No insertions or deletions were detected using the specifically designed probes. No mutations were detected by either technique in the remainder of the patients and therefore the cause of ‘low-normal gGT’ cholestasis remains undetermined in these cases. The negative results in these cases may be explained by whole exon deletions or duplications, intronic mutations affecting splicing, or promoter region mutations in \( \text{ATP8B1} \) and \( \text{ABCB11} \), as such mutations would not be detected by either strategy. In addition, it is possible that further genes are involved in the phenotype of neonatal cholestasis with low gGT.

In sample 17, MR detected a variant not confirmed by FS, constituting a false positive result. Two samples (6 and 22) had compound heterozygous changes in \( \text{ATP8B1} \) detected by FS but not by MR. Both samples had two variants in close proximity; therefore we speculate that these are in cis and that each sequence variant has impaired the hybridisation of surrounding probes. Our experience of testing patients for mutations in these genes suggests that false negative results arising in this manner are likely to be uncommon. However, in this cohort they occurred in 7% of samples.
Discussion

MR is an alternative to FS because it allows for the rapid and cost-effective genetic screening of a large number of genes in one experiment. The BRUM1 microarray used in this study has a much larger capacity than was utilised in the experience described here, as it contains probes for 92 genes associated with inherited disorders. Analysis of the ability of this microarray to detect known gene mutations has shown a 97% mutation detection rate for base substitutions. We recommend that MR methods be used for the detection of base substitutions (both false negative and false positive calls), are frequent and were found in approximately 10% of samples in this study.

Of the mutations recorded in the Human Gene Mutation Database1 in ATP8B1 and ABCB11, 24% and 16% respectively were small insertions or deletions (indels), although their combined frequency in PFIC cases is unknown as most are private mutations. The major advantage of MR is its insensitivity for the detection of indels1. Whilst known indels can be detected with proper microarray design, novel indels will be missed. Larger insertions and deletions involving whole exons, of the type routinely detected by multiplex ligation-dependent probe amplification (MLPA; MRC-Holland, Netherlands), are not detected by either MR or FS. Another disadvantage, underscored by the results of this study, is that mis-called base substitutions (both false negative and false positive calls), are frequent and were found in approximately 10% of samples in this study.

In conclusion, MR allows rapid and cost-effective genetic screening in neonatal cholestasis and yields results relevant for patient management. Many clinical laboratories are experienced in oligoarray comparative genome hybridization (CGH) and thus have access to equipment required for MR, suggesting that MR could be implemented for a relatively small monetary investment. In principle, MR could be applied to many clinical scenarios involving heterogeneous conditions, especially if the mutations tend to be base substitutions. We recommend that MR methods be used for initial evaluation, with FS deployed when genetic and clinical or histopathologic findings are discordant.
Consent
Consent for research into the genetic cause of the patients’ cholestasis was obtained from the patients’ legal guardian at the time of obtaining the sample.

Author contributions
KEM performed the experiments, analysed the data and prepared the first draft of the manuscript. CKB performed the experiments and analysed the data. SSB recruited patients and performed experiments. UB, ES, DAK, CJK and JLH recruited patients and analysed the data. ASK and FMcD analysed the data. PG conceived the study and analysed the data. All authors were involved in the revision of the manuscript and have agreed to the final content.

Competing interests
No competing interests were disclosed.

Grant information
The funding for reagents was supported by an educational grant from Actelion Pharmaceuticals.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Open Peer Review

Current Referee Status: ✔️ ❓

Version 1

Referee Report 14 February 2013
doi:10.5256/f1000research.301.r770

Andrea Ballabio
Telethon Institute of Genetics and Medicine, Naples, Italy

The authors compare, in a very thorough and detailed manner, the performance of Microarray resequencing (MS) vs. Sanger sequencing (FS) for mutation detection in the ATP8B1 and ABCB11 genes in cholestatic patients. They recommend the cautious use of microarray resequencing as an initial evaluation tool and propose to limit the use of Sanger sequencing to more problematic and discordant cases.

However, given the non-negligible discordance observed by the authors between the two approaches (MR had a false positive rate of 3.4% and a false negative rate of 7%), the definition of the cases that should be analyzed by FS is not entirely clear. Moreover, a number of other resequencing procedures that can be applied to the simultaneous analysis of multiple genes are now available. Some of them are very competitive in terms of efficacy and cost with MS and it is quite likely that in the near future they will be more widely used with respect to MS. Ideally, the authors should have discussed about this issue.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Competing Interests: No competing interests were disclosed.

Referee Report 14 February 2013
doi:10.5256/f1000research.301.r769

Struan Grant
Center for Applied Genomics, Children's Hospital of Philadelphia Research Institute, University of Pennsylvania, Philadelphia, PA, USA

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.